Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1344635

registered interest
date	07/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish the covid-19 transmission rates for people who have had (a) one vaccine and (b) two vaccines for each of the different vaccines.
tabling member constituency	York Central
tabling member printed	Rachael Maskell
uin	29085
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The following table shows the latest summary of evidence on vaccine effectiveness against different outcomes, including transmission, for Pfizer/BioNTech and University of Oxford/AstraZeneca as of 1 July 2021.</p><p> </p><table><tbody><tr><td rowspan="3"><p>Outcome</p></td><td colspan="4"><p>Vaccine Effectiveness</p></td></tr><tr><td colspan="2"><p>Pfizer/BioNTech</p></td><td colspan="2"><p>Oxford/AstraZeneca</p></td></tr><tr><td><p>1 dose</p></td><td><p>2 doses</p></td><td><p>1 dose</p></td><td><p>2 doses</p></td></tr><tr><td><p>Symptomatic disease</p></td><td><p>55-70%*</p></td><td><p>85-95%*</p></td><td><p>55-70%*</p></td><td><p>70-85%**</p></td></tr><tr><td><p>Hospitalisation</p></td><td><p>75-85%*</p></td><td><p>90-99%**</p></td><td><p>75-85%*</p></td><td><p>80-99%***</p></td></tr><tr><td><p>Mortality</p></td><td><p>70-80%**</p></td><td><p>95-99%**</p></td><td><p>75-85%**</p></td><td><p>75-99%***</p></td></tr><tr><td><p>Infection</p></td><td><p>55-70%**</p></td><td><p>70-90%***</p></td><td><p>60-70%***</p></td><td><p>No data</p></td></tr><tr><td><p>Transmission (secondary cases)^</p></td><td><p>45-50%***</p></td><td><p>No data</p></td><td><p>35-50%***</p></td><td><p>No data</p></td></tr></tbody></table><p> </p><p>Source: Table 3, <a href="https://eur01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.gov.uk%2Fgovernment%2Fpublications%2Fcovid-19-vaccine-surveillance-report&amp;data=04%7C01%7Ccovid19surv%40phe.gov.uk%7Cb2598e32058644d021bf08d916c0fea2%7Cee4e14994a354b2ead475f3cf9de8666%7C0%7C0%7C637565840415583246%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C1000&amp;sdata=MFmH8qQxqsBUGSNXnO5e7tyCyPWBtYpuq%2FF3GUfu6AI%3D&amp;reserved=0" target="_blank">https://www.gov.uk/government/publications/covid-19-vaccine-surveillance-report</a></p><p> </p><p>Notes:</p><ol><li>*High Confidence - Evidence from multiple studies which is consistent and comprehensive.</li><li>**Medium Confidence - Evidence is emerging from a limited number of studies or with a moderately level of uncertainty.</li><li>***Low Confidence - Little evidence is available at present and results are inconclusive.</li><li>^effectiveness in reducing symptomatic secondary cases in households of a symptomatic index case.</li></ol><p> </p><p>Public Health England plans to publish vaccine effectiveness data for Moderna when more evidence becomes available.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 15:50:18 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4471 label Biography information for Rachael Maskell

1344767

registered interest
date	07/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Travel: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his officials are having with their counterparts in the European Commission on potential travel restrictions for UK citizens who have had the AstraZeneca vaccine produced by the Serum Institute of India.
tabling member constituency	South Shields
tabling member printed	Mrs Emma Lewell-Buck
uin	29059
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The Government continues to engage the European Union on certification to ensure that travel between the United Kingdom and the EU is unhindered and supported by a common approach.</p><p>The Serum Institute of India (SII) manufactures Vaxzevria and Covishield and both branded vaccines are the same as the University of Oxford/AstraZeneca vaccine. All SII-made doses approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) and administered in the UK were branded as the ’COVID-19 vaccine AstraZeneca’ which is now known commercially as ‘Vaxzevria’. The MHRA has not approved doses branded as ‘Covishield’ and none have been administered in the UK. All AstraZeneca vaccines given in the UK are the same product and appear on the NHS COVID Pass as Vaxzevria. The European Medicines Agency has authorised Vaxzevria vaccine and it is therefore recognised by the EU.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 16:51:11 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4277 label Biography information for Mrs Emma Lewell-Buck

1344800

registered interest
date	07/07/2021
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Iron and Steel: Manufacturing Industries
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, with reference to trials, pilots and full-scale projects underway in countries including France, Austria, Germany, Netherlands, Spain, Sweden, Italy on using hydrogen to produce primary steel, what steps she is taking to ensure steel production in the UK keeps pace with international competitors on developing and using clean steel production technology.
tabling member constituency	Na h-Eileanan an Iar
tabling member printed	Angus Brendan MacNeil
uin	29000
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The UK is monitoring international progress on low carbon steel making trials, using hydrogen and other technologies, and is actively engaged in international initiatives to support industrial decarbonisation innovation, including the Mission Innovation platform and the Leadership Group for Industry Transition.</p><p> </p><p>Decarbonising UK industry is a core part of the Government’s ambitious plan for the green industrial revolution. The Industrial Decarbonisation Strategy, published on 17 March, commits government to work with the Steel Council to consider the implications of the recommendation of the Climate Change Committee to ‘set targets for ore-based steelmaking to reach near-zero emissions by 2035’. The Steel Council is a forum for Government, industry and trade unions to work together on the shared objective of creating a competitive, sustainable and low carbon future for the sector. Hydrogen-based steelmaking is one of the technological approaches being examined as part of this process.</p><p> </p><p>The UK steel sector will be given the opportunity to bid into industrial fuel switching innovation programmes under the £1 billion Net Zero Innovation Portfolio (NZIP), which is intended to promote switching away from more carbon-intensive fuel sources. The Government has also announced a £250 million Clean Steel Fund to support the UK steel sector to transition to lower carbon iron and steel production, through investment in new technologies and processes.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 15:13:23 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	1546 label Biography information for Angus Brendan MacNeil

1344802

registered interest
date	07/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with the Joint Committee on Vaccination and Immunisation on the potential merits of reducing the gap between first and second covid-19 vaccinations to three-to-six weeks; and whether there is sufficient vaccine supply to meet that arrangement.
tabling member constituency	Newton Abbot
tabling member printed	Anne Marie Morris
uin	29051
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>Currently, the Joint Committee on Vaccination and Immunisation (JCVI) recommends an interval of eight weeks between doses of all the available COVID-19 vaccines. On 14 May, we amended the interval of second doses for the most vulnerable cohorts who were offered a vaccine in phase one of the programme, from 12 weeks to eight weeks. The eight week dose interval was applied to all eligible cohorts from 6 July.</p><p>Current evidence shows that a longer dose interval produces a better immune response. As such, the JCVI has advised against reducing the dose interval further in order to maximise the effectiveness of the vaccination programme. The JCVI regularly reviews its advice taking into account new data and evidence on the effectiveness of the programme and epidemiological situation.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/07/2021 11:51:20 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 13483 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4249 label Biography information for Anne Marie Morris

1344819

registered interest
date	07/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pregnancy: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will publish data on the number of pregnant and breastfeeding women who have had covid-19 vaccinations.
tabling member constituency	Battersea
tabling member printed	Marsha De Cordova
uin	29137
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The data is not held centrally in the format requested.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 15:52:52 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4676 label Biography information for Marsha De Cordova

1344110

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus Certificates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that UK residents vaccinated against covid-19 whilst abroad are able to be certified as so vaccinated in the UK.
tabling member constituency	Luton North
tabling member printed	Sarah Owen
uin	28345
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>Work is ongoing to determine which non-United Kingdom vaccines can be recognised in this country.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 14:17:26 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4777 label Biography information for Sarah Owen

1344131

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Travel: Coronavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has received confirmation from EU counterparts that UK citizens who are fully vaccinated against covid-19 will not find their travel to EU countries affected as a result of their having received a dose of the AstraZeneca covid-19 vaccine from batch numbers 4120Z001, 4120Z002 or 4120Z003.
tabling member constituency	Ceredigion
tabling member printed	Ben Lake
uin	28293
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The Serum Institute of India (SII) manufactures both Vaxzevria and Covishield, branded vaccines which are the same as the University of Oxford/AstraZeneca vaccine. All SII-made doses approved by the United Kingdom regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) and administered in the UK were branded as the ’COVID-19 vaccine AstraZeneca’ which is now known commercially as ‘Vaxzevria’. The MHRA has not approved doses branded as ‘Covishield’ and none have been administered in the UK. All AstraZeneca vaccines given in the UK are the same product and appear on the NHS COVID Pass as Vaxzevria.</p><p>The European Medicines Agency has authorised the Vaxzevria vaccine and it is therefore recognised by the European Union.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 08:43:57 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4630 label Biography information for Ben Lake

1344202

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will make it his policy to prioritise potential covid-19 booster vaccinations for (a) people living with asthma and (b) unpaid carers.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	28275
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>The JCVI advises a two staged approach, with individuals in stage one offered a booster vaccine and flu vaccine as soon as possible from September. Individuals in stage two should be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at risk group which includes some sufferers of chronic respiratory disease and asthma, are currently included in stage two.</p><p>Based on the JCVI’s interim advice, those eligible in phase one of the COVID-19 vaccination programme are likely to be offered a booster which includes unpaid carers. Final decisions on the timing, scope and cohort eligibility, of any booster programme will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 14:20:52 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4523 label Biography information for Catherine West

1344306

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many people in the UK have received the Covishield covid-19 vaccine since the start of the covid-19 vaccination roll-out.
tabling member constituency	Hornsey and Wood Green
tabling member printed	Catherine West
uin	28277
answer	answer is ministerial correction date of answer 13/07/2021 answer text <p>The Medicines and Healthcare products Regulatory Agency has not approved doses branded as ‘Covishield’ and therefore none have been administered in the United Kingdom.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 13/07/2021 11:53:31 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4523 label Biography information for Catherine West

1344339

registered interest
date	06/07/2021
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Coronavirus: Vaccination
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department plans to prioritise people with (a) asthma and (b) other respiratory conditions for the covid-19 booster vaccination.
tabling member constituency	Jarrow
tabling member printed	Kate Osborne
uin	28348
answer	answer is ministerial correction date of answer 12/07/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) published interim advice on a potential COVID-19 booster vaccination programme on 30 June, which is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022" target="_blank">https://www.gov.uk/government/publications/jcvi-interim-advice-on-a-potential-coronavirus-covid-19-booster-vaccine-programme-for-winter-2021-to-2022</a></p><p>The JCVI advises a two staged approach, with individuals in stage one offered a booster and flu vaccine, as soon as possible from September. Individuals in stage two should be offered a COVID-19 booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at-risk group, such as sufferers of chronic respiratory conditions and asthma are included in stage two.</p><p>Final decisions on the timing and scope and cohort eligibility, will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 12/07/2021 14:26:23 answering member 4113 label Biography information for Nadhim Zahawi
tabling member	4783 label Biography information for Kate Osborne